PEGASUS - A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial to Assess the Prevention of Thrombotic Events with Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Pts w/History of MI
Description of Research
This study is being carried out to see if a new, investigational drug called ticagrelor given twice daily in addition to the aspirin therapy that you are already using decreases the frequency of cardiovascular events (e.g., death from heart disease, heart attack, or stroke). An investigational drug is a drug that is being tested and is not approved for sale in the United States by the U.S. Food and Drug Administration (FDA).
For patients who have had at least 1 heart attack (what physicians call a myocardial infarction) from 1 to 3 years ago and are presently treated with aspirin to prevent new heart attacks. In addition you are either 65 years of age or older or suffering from at least 1 of the following medical conditions: diabetes, atherosclerosis (plaque build-up) in more than 1 of the arteries that supply the heart, more than 1 prior heart attack, or a chronic decrease of kidney function.